FSD Pharma Strengthens Management Team

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

[{"type":"text","content":"\n\n\n\nFSD Pharma Strengthens Management Team\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO, Jan. 2, 2020\n\n\n\n- Donal Carroll Appointed Chief Financial Officer, Dr. Sandra Lottes as Vice President and Head of Clinical Research at BioSciences Division, and Shahzad Shah as Chief Operating Officer at FV Pharma - \n TORONTO, Jan. 2, 2020 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (\"FSD Pharma\" or the \"Company\") today announced the appointments of three key executives: Donal Carroll, Chief Financial Officer. Mr. Carroll previously served as interim CFO; Sandra Lottes, Pharm D, Vice President & Head of Clinical Research of FSD Pharma's BioSciences Division; and Shahzad Shah, Chief Operating Officer of FV Pharma.\n\n \n \n\n \n\"We are very excited to have Mr. Donal Carroll transition into a permanent leadership role and are thrilled to welcome Dr. Sandra Lottes and Mr. Shahzad Shah to the FSD Pharma executive team, as we begin to write the next chapter of FSD Pharma in the new year,\" said Raza Bokhari, MD, Executive Co-Chairman and CEO. \"Mr. Carroll has been the interim CFO since July 2018 and has a deep understanding of our core business and strategic outlook to transform FSD Pharma into a specialty pharmaceutical R&D company. We couldn't be more fortunate for Donal to accept the role of the full-time CFO, as we prepare to begin trading on the Nasdaq Capital Market soon. \n\"Dr. Lottes brings to FSD Pharma almost three decades of pharmaceutical, contract research organization, and healthcare industry experience. Her expertise spans the drug development, commercialization and product lifecycle continuum that makes her an important and timely addition to the FSD Pharma Biosciences team as we prepare to launch Phase 1 human safety trials for our lead candidate, PP 101 micro-PEA.\n\"Mr. Shah has a proven track record of bringing discipline and operational efficiency to organizations. I have worked with Shahzad in the past and I expect his experience to strike the right bal...

More updates from Quantum Biopharma Ltd. Subordinate Voting Shares Class B